Multiplex PCR test for detection of enteropathogens in an infant

CAP TODAY and the Association for Molecular Pathology have teamed up to bring molecular case reports to CAP TODAY readers. AMP members write the reports using clinical cases from their own practices that show molecular testing’s important role in diagnosis, prognosis, and treatment. Case report No. 10, which begins here, comes from Diatherix Laboratories. If you would like to submit a case report, please send email to the AMP at ampinfo@amp.org. For more information about the AMP and all previously published case reports, visit www.amp.org.

Donald Lazas, MD
Leslie C. Ber, MD
Elena Grigorenko, PhD
Don Stalons, PhD, D(ABMM), MPH

Clostridium difficile is an anaerobic spore-forming, Gram-positive bacte- ria transmitted by the fecal-oral route. The virulence of Clostridium difficile is primarily conferred from two toxins, A and B. Disruption of the normal gut flora, typically from intake of antimicrobials, allows Clostridium difficile to proliferate, caus- ing a broad spectrum of clinical symptoms from asymptomatic coloni- zation to colitis, a spectrum of diar- rhea severity, and a protracted course of disease. The incidence of Clostridium difficile infection (CDI) among hospitalized children has increased dramatically in the past decade. Here, we report on a case of Clostridium difficile and Salmonella enterica co-infection in a seven-month-old patient with previous antibiotic treatment for simianis us- ing Augmentin. The presence of Sal- monella enterica detected in this pat- ient may have acted synergistically or compounded the symptoms of the infection.

Introduction. Infectious diarrheal diseases are the second leading cause of mortality and morbidity, and age-specific rates are highest for children under age three. Although CDI pre- dominantly affects adult and elderly populations, a recently published retrospective cohort study suggested that pediatric CDI is associated with increased mortality, longer hospitalization, and higher patient care costs. The pediatric population, previously considered at low risk for CDI, has had an increased incidence of CDI-associated hospital admis- sions. Although testing of infants is not recommended, recent data have shown that 26 percent of children hospitalized with CDI were infants younger than one year and five per- cent were neonates. Recognized risk factors for children with detected CDI include extensive antimicrobial therapy, gastrointestinal surgeries, frequent hospitalizations, and im- paired immunity. Breastfed infants have a lower carriage rate of Clostridium difficile compared with formula-fed infants. This pediatric population group may be asymptom- atic for Clostridium difficile in- fection in the face of a positive test when the colonic wall receptor site for toxin may be nonfunctional or immature. Although the conventional stool culture is the well-established diag- nostic tool for enteric pathogens, its effectiveness is very low, with report- ing times ranging from two to four days, and it may be less sensitive than molecular methods. Furthermore, widespread use of antibiotics can adversely affect the growth of potential pathogens in bacterial cul- ture, rendering false-positive or false- negative results. PCR amplification has emerged as a useful tool to detect

adenovirus 40, and adenovirus 41. Target-enriched multiplex PCR (TEM-PCR) is the core molecular technology used for this panel. Nesta- tive gene-specific primers at extremely low concentrations are used to am- plify targets during the first few cy- cles of PCR of the target-enrichment step. This is followed by exponential amplification using universal SuperPrimers. The Reverse SuperPrimer is labeled with biotin for subse- quent detection of amplicons (Fig. 1A). The concentration of Forward and Reverse SuperPrimers facilitates asymmetric PCR producing biotin- labeled PCR products (Fig. 1B).

a rectal swab stool specimen was obtained and submitted for labora- tory testing with Diatherix’s gastro- intestinal panel. Nucleic acid extrac- tions, multiplex PCR amplification, and positive/negative signal detec- tion were performed at the CLIA- certified Diatherix Laboratories. The results were reported to the physi- cian’s office within seven hours of the sample having been received for laboratory testing. The patient’s rect- al swab sample was positive for both C. difficile toxin B and Salmo- nella enterica. The patient was treat- ed preferentially with a seven-day course of ampicillin for Salmonella enterica. Diarrhea subsequently re- solved without recurrence.

Discussion. The significance of Clostridium difficile as a cause of gastroenteritis in the pediatric popu- lation has been a subject of debate for decades. Studies that have docu- mented early colonization of the bowel flora in neonates and the ap- parent lack of symptoms in the face of positive cultures for the organism and the presence of toxin have cast doubt on the significance of Clostridium difficile in this patient group. However, the emergence of a more virulent strain of Clostridium difficile that produces a binary toxin (BI/NAP1/027) has led to a significant rise in the preva- lence of the organism in hospitalized children who do not have comorbid factors. As a result, there has been a shift in the spectrum and prevalence of the disease in the pediatric popu- lation over the past decade.

Clinical presentation does not al- ways provide direction for the diag- nosis of gastroenteritis whether in the adult or pediatric patient. Early stages of Clostridium difficile infec- tion are usually accompanied by mild diarrhea (five to 10 watery stools a day), low-grade fever, and mild abdominal cramping and ten- derness. In the more severe forms of the disease, fever (usually 102°F to 104°F), severe diarrhea (more than 10 watery stools a day) with blood, and marked abdominal pain and tender- ness are present.

infection in the face of a positive test when the colonic wall receptor site for toxin may be nonfunctional or immature. Although the conventional stool culture is the well-established diagnostic tool for enteric pathogens, its effectiveness is very low, with reporting times ranging from two to four days, and it may be less sensitive than molecular methods. Furthermore, widespread use of antibiotics can adversely affect the growth of potential pathogens in bacterial culture, rendering false-positive or false-negative results. PCR amplification has emerged as a useful tool to detect adenovirus 40, and adenovirus 41. Target-enriched multiplex PCR (TEM-PCR) is the core molecular technology used for this panel. Nesterative gene-specific primers at extremely low concentrations are used to amplify targets during the first few cycles of PCR of the target-enrichment step. This is followed by exponential amplification using universal SuperPrimers. The Reverse SuperPrimer is labeled with biotin for subsequent detection of amplicons (Fig. 1A). The concentration of Forward and Reverse SuperPrimers facilitates asymmetric PCR producing biotin-labeled PCR products (Fig. 1B).

pathogen DNA and RNA rapidly (four to six hours) with higher sensi- tivity and specificity. Multiplex PCR-based tests for the detection of enteric pathogens in a single stool specimen are well suited to clinical purposes.

The gastrointestinal panel developed by Diatherix Laboratories (Huntsville, Ala.) provides simultaneous detection of the following pathogens: Clostridium difficile toxin B gene, Campylobacter jejuni, Esch- erichia coli strain O157, Listeria monocytogenes, Salmonella enterica, Shigella flexneri, Shigella sonnei, Vibrio parahaemolyticus, Giardia lamblia, Cryptosporidium parvum, These PCR products are hybridized to a complementary target-specific probe covalently coupled to a glass microarray (Microarrays Inc.) and detected with Streptavidin-labeled Phycoerythrin conjugate. Fluorescent signal corresponding to hybridized PCR products is detected on FLAIR reader (Sensovation, Ger- many), and results are reported as positive or negative for pathogens detected in the gastrointestinal panel.

Case. A seven-month-old female presented with a three-day history of diarrhea. The patient’s mother re- ported that the child was passing four to five bloody stools per day and experiencing low-grade fevers. The child’s oral intake remained normal and no abdominal pain was reported. The patient had been seen two weeks prior to the current visit with purulent nasal drainage and was treated with a seven-day course of Augmentin for sinusitis. Past medical history was unremarkable and the patient was on no long-term medications. Physical exam revealed a well-nourished child in no appar- ent distress. Tympanic temperature was 99.2°F and heart rate was 124. Oral mucous membranes were moist and skin turgor was normal. The abdominal exam revealed normal active bowel sounds and no tender- ness or mass.

---continued on 46
Multiplex PCR
continued from 44

These symptoms are not unique, however, as there is overlap with other intestinal pathogens that have both toxin and invasive components.

This case also exhibits co-detection of *Clostridium difficile* toxin B in association with a second pathogen, *Salmonella enterica*. In the new era of molecular diagnostics and specifically multiplex PCR in which multiple pathogens can be detected in a single specimen, clinicians are faced with a new level of information. The traditional paradigm wherein one pathogen causes clinical infection may be under challenge. Co-pathogens may work synergistically to cause clinical disease. Future molecular diagnostic testing will need to include, in addition to pathogen detection, other features that assist in determining pathogenesis and clinical illness.

We have presented this case report to draw attention to the fact that the spectrum and etiology of gastroenteritis in the pediatric population may be changing and molecular diagnostic tests are necessary to uncover complex etiology behind appropriate diagnosis and treatment of the pediatric population.


Dr. Lazas is with Associates in Gastroenterology PLC, Nashville, Tenn., and Dr. Ber is with Sugarland Pediatrics LLC, Houston, La. Dr. Grigorenko is vice president of research and development, and Dr. Stalons is vice president of operations and clinical laboratory director—both at Diatherix Laboratories, Huntsville, Ala.